A national, multi-centre, longitudinal observational study evaluating the efficacy and safety under real-life conditions of use of TALZENNA® (talazoparib) in patients with somatic or germline BRCA mutated HER2 negative, locally advanced or metastatic breast cancer (Vital Study)